Pharmaceutical The UK's National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending Sarclisa (isatuximab) alongside the existing treatments of pomalidomide and dexamethasone for adults with relapsed/refractory multiple myeloma who have received three prior lines of treatment and at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last treatment. 15 October 2020